Châtillon, France, July 29, 2025




DBV Technologies announces filing of 2025 Half-Year
Report ― Conditions for accessing or consulting the Report
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT), a clinical-stage biopharmaceutical company focused on treatment options
for food allergies and other immunologic conditions with significant unmet medical
need (the “Company”), today announced the filing, for the semester ended June 30,
2025, of its Half-Year Report with the French market authority, “Autorité des
Marchés Financiers” (“AMF”).

The 2025 Half-Year Report can be consulted or downloaded from the Company’s
website (www.dbv-technologies.com) in the section Investors/Financial
Information, and on the AMF website (www.amf-france.org), in French only.

It is also available free of charge upon request:
- by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ;
- by email: investors@dbv-technologies.com.


About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV is currently focused on investigating the use
of its proprietary VIASKIN® patch technology to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a range of
symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of
people live with food allergies, including young children. Through epicutaneous
immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram
amounts of a biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to modify an
individual’s underlying allergy by re-educating the immune system to become
desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV
is committed to transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic
toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs
(each representing five ordinary shares) are traded on the Nasdaq Capital Market
(Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us
on X (formerly Twitter) and LinkedIn.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com